From the publishers of JADPRO

Metastatic Triple-Negative Breast Cancer Resource Center

Advertisement

KEYNOTE-355 Final Analysis Reveals Survival Benefit With Pembrolizumab in Triple-Negative Breast Cancer

Last Updated: Tuesday, April 5, 2022

The final overall survival results from the KEYNOTE-355 study showed a statistically significant 27% reduction in the risk of death for patients with metastatic triple-negative breast cancer whose tumors were strongly positive for PD-L1, defined as a combined positive score (CPS) of at least 10 and who received pembrolizumab vs placebo combined with chemotherapy as first-line therapy.

The ASCO Post
Advertisement
News & Literature Highlights
Advertisement
Advertisement